FTLF FITLIFE BRANDS, INC.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1374328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.5%
TTM net income YoY1.9%
TTM EPS YoY1.5%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR17.1%
Margins
Gross margin36.7%
Operating margin11.0%
Net margin6.7%
FCF margin4.5%
EBITDA margin11.9%
Returns
ROE15.1%
ROA6.4%
ROIC (approx.)13.8%
Asset turnover0.96x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.64x
Interest coverage3.93x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio2.0%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $81.46M | $64.47M | $52.70M | $28.80M | $27.91M |
| Cost of revenue | $50.01M | $36.39M | $31.27M | $16.77M | $15.41M |
| Gross profit | $31.45M | $28.08M | $21.43M | $12.03M | $12.50M |
| SG&A expense | $14.04M | $9.97M | $7.88M | $6.01M | $6.21M |
| Operating income | $10.06M | $13.12M | $7.55M | $5.70M | $6.23M |
| Interest expense | $1.86M | $1.37M | $1.02M | $0 | — |
| Pretax income | $8.23M | $11.87M | $7.00M | $5.82M | $6.71M |
| Income tax | $1.90M | $2.89M | $1.71M | $1.39M | $1.30M |
| Net income | $6.33M | $8.98M | $5.30M | $4.43M | $5.41M |
| EBITDA | $10.48M | $13.23M | $7.64M | $5.77M | $6.29M |
| EPS (basic) | 0.68 | 0.98 | 0.59 | 0.97 | 1.23 |
| EPS (diluted) | 0.63 | 0.91 | 0.54 | 0.89 | 1.13 |
| Weighted avg. shares (diluted) | 9.98M | 9.90M | 9.81M | 4,975 | 4.80M |
| Banking | |||||
| Net interest income | — | — | — | $121,000 | $25,000 |
| Balance sheet | |||||
| Cash & equivalents | $1.65M | $4.47M | $1.14M | $13.28M | $9.90M |
| Receivables | $8.77M | $1.63M | $2.05M | $705,000 | $945,000 |
| Inventory | $21.32M | $11.07M | $9.09M | $9.11M | $6.52M |
| Current assets | $33.07M | $18.14M | $14.69M | $23.20M | $17.68M |
| PP&E, net | $128,000 | $75,000 | $137,000 | $46,000 | $70,000 |
| Goodwill | $19.39M | $13.02M | $13.29M | $358,000 | $358,000 |
| Intangibles | $51.44M | $26.23M | $26.31M | $150,000 | $192,000 |
| Total assets | $106.32M | $58.53M | $55.35M | $25.71M | $21.51M |
| Current liabilities | $21.61M | $11.31M | $10.34M | $4.27M | $4.06M |
| Short-term debt | — | $4.50M | — | $0 | — |
| Long-term debt | — | $8.55M | $15.51M | $0 | — |
| Total debt | — | $13.05M | $15.51M | $0 | — |
| Total liabilities | $62.68M | $22.41M | $28.31M | $4.32M | $4.16M |
| Shareholders' equity | $43.64M | $36.13M | $27.04M | $21.39M | $17.35M |
| Net debt | — | $8.58M | $14.37M | -$13.28M | — |
| Shares outstanding | 9.39M | 9.21M | 9.20M | 4.51M | 4.55M |
| Cash flow statement | |||||
| Operating cash flow | $7.44M | $9.61M | $4.22M | $4.13M | $4.48M |
| Capital expenditure | $42,000 | $10,000 | $106,000 | $0 | — |
| Free cash flow | $7.40M | $9.60M | $4.11M | $4.13M | — |
| Investing cash flow | -$42.54M | -$10,000 | -$35.99M | $0 | -$529,000 |
| Financing cash flow | $32.09M | -$6.98M | $20.30M | -$750,000 | -$390,000 |
| Depreciation & amortization | $420,000 | $108,000 | $94,000 | $66,000 | $59,000 |
| Stock-based compensation | — | — | — | $76,000 | $100,000 |
| Share buybacks | — | — | $0 | $779,000 | $444,000 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.